Die-hard optimists who think that the Food & Drug Administration’s drug review process isn’t influenced by Capitol Hill politics, think again.
The recent congressional attention on the safety of Sanofi-Aventis’ telithromycin (Ketek) is making FDA more cautious when it comes to...






